Drug
Bibw 2992
Bibw 2992: highest development phase Phase 2, developed by Boehringer Ingelheim. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| BIBW 2992 NCT01156545 | Phase 2 | Non-small Cell Lung Cancer |
| BIBW 2992 NCT00998296 | Phase 1 | Neoplasms |
| BIBW 2992 NCT02171637 | Phase 1 | Neoplasms |
Latest
No recent events.
Follow Bibw 2992 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.